Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01165697 · ClinicalTrials.gov registry record
Establishment of Biomarkers for Fabry Disease
A clinical trial, sponsored by Ohio State University.
- Completed
- Registry status
- 4
- Enrollment target
NCT01165697 is a clinical trial that has completed, run by Ohio State University. The registered enrollment target is 4 participants.
The verdict
NCT01165697 has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
Study Summary
Fabry disease, an x-linked recessive lysosomal storage disease (LSD) is commonly recognized as a cause of renal failure in involved men and more recently recognized in women too. Women are involved in significant numbers and with complications, as are men, of vascular disease. This manifests as unexpected strokes in young adults. We have morphologic evidence that storage-endotheliopathy induced microvascular disease is the cause of cardiopathy and of cryptogenic strokes, and that storage endotheliopathy starts in early life, probably before birth. Based on our earlier work with other endotheliopathies such as diabetes mellitus, Susac syndrome, and hypertension, we will find and study patients using unique methods, neuro-retinal fluorescein angiography (NRFA), that we have developed for this purpose. These methods include NRFA to demonstrate capillary perfusion in the optic nerve head and retinal quadrants. We anticipate, based on our earlier experience with other endotheliopathies, that we will show more vascular pathology earlier than previously reported. Using epidemiologic and genetic tools we will find more patients than previously known or expected. It will offer opportunity for earlier diagnosis, prognosis, and response to enzyme replacement therapy. We hypothesize that Fabry disease is a poorly recognized and poorly characterized cause of microvascular disease and cryptogenic strokes in young women and men. Neuroretinal capillary perfusion abnormalities in Fabry disease will be predictive of equivalent vascular disease in kidney, heart, brain and other organs, and further that it will be responsive to change induced by enzyme replacement therapy treatment.
Interventions
- OTHER Fluorescein angiography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-07 |
| Est. Completion | 2014-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01165697
The ClinicalTrials.gov registry entry for NCT01165697 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fluorescein angiography is the first listed.
NCT01165697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01165697 about?
NCT01165697 is a clinical study titled "Establishment of Biomarkers for Fabry Disease". Fabry disease, an x-linked recessive lysosomal storage disease (LSD) is commonly recognized as a cause of renal failure in involved men and more recently recognized in women too. Women are involved in significant numbers and with complications, as are men, of vascular disease. This manifests as unex...
What is the current status of trial NCT01165697?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2010-07. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01165697?
The interventions under investigation include: Fluorescein angiography (OTHER).
Who is sponsoring clinical trial NCT01165697?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.